The QualityStocks Daily Monday, August 2nd, 2021

Today's Top 3 Investment Newsletters

Fierce Analyst(GTHR) $0.0895 +325.38%

MarketClub Analysis(EVK) $5.0800 +124.78%

QualityStocks(INFI) $2.9300 +38.21%

The QualityStocks Daily Stock List

Transocean (RIG)

Schaeffer's, MarketClub Analysis, The Street, InvestorPlace, Barchart, StreetInsider, TopStockAnalysts, MarketBeat, Streetwise Reports, Zacks, SmarTrend Newsletters, StreetAuthority Daily, All about trends,, Daily Trade Alert, The Growth Stock Wire, Market Report, StocksEarning, Daily Wealth, Investopedia, Street Insider, The Online Investor, Uncommon Wisdom, Buttonwood Research, VectorVest, Kiplinger Today, StreetAlerts, INO Market Report, Trades Of The Day, ProfitableTrading, Investors Alley, Investing Daily, Energy and Capital, Market Intelligence Center Alert, Dividend Opportunities, TradingAuthority Daily, Trade of the Week, TheStockAdvisors, Investor Guide, Daily Markets, Money Morning, Short Term Wealth, Money and Markets, Forbes, One Hot Stock, InvestorGuide, Investing Futures, Schaeffer’s, Turn Key Oil, The Best Newsletters, Super Stock Investor, Wealth Insider Alert, The Weekly Options Trader, The Motley Fool, Investiv, Trading Concepts, The Street Report, The Tycoon Report, Investment House, QualityStocks, Insider Wealth Alert, Inside Investing Daily, TradingMarkets, Hit and Run Candle Sticks, Wall Street Greek, WStreet Market Commentary, OTC Picks, SmallCapVoice, Wyatt Investment Research, Stockhouse, MomentumBeats, BUYINS.NET, Cabot Wealth, StockMarketWatch, Coattail Investor, Dynamic Wealth Report, CrashTrade, Wealth Daily, Early Bird, WallStreetBeats and Candle Stick Forum reported earlier on Transocean (RIG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Transocean Ltd (NYSE: RIG) (BMV: RIGN) is an offshore drilling contractor that is focused on the provision of contract drilling services for gas and oil wells across the globe.

The firm has its headquarters in Steinhausen, Switzerland and was incorporated in 1953. It operates as part of the support activities for the mining industry, under the mining sector. The firm has two companies in its corporate family and serves consumers around the world.

The company’s main business is to contract its work crews, drilling rigs and related equipment to drill gas and oil wells. It specializes in technically demanding segments of the offshore drilling business, which include harsh environment drilling services and deep-water drilling services. The company serves government-controlled or government-owned oil companies, integrated oil companies and other independent oil companies.

The enterprise’s contract drilling service operations are spread across gas and oil exploration and development areas in different parts of the globe. It owns and operates inland drilling barges, mobile offshore drilling units and other assets used to support offshore drilling activities across the globe. As of February 2021, the enterprise had partial ownership interests in or owned and operated a fleet of 37 mobile offshore drilling units. These include ten harsh environment floaters and 27 ultra-deep water floaters.

The firm recently announced that it had been awarded a pair of contracts which contribute about $56 million in backlog. This move builds confidence in the company’s high-quality services and will help extend their consumer reach and also bring in more investors into the firm, which will boost the company’s growth.

Transocean (RIG), closed Monday's trading session at $3.61, even for the day, on 29,678,899 volume with 52,400 trades. The average volume for the last 3 months is 25.705M and the stock's 52-week low/high is $0.649999976/$5.13000011.

Cloopen Group Holding (RAAS)

MarketBeat reported earlier on Cloopen Group Holding (RAAS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cloopen Group Holding Limited (NYSE: RAAS) is a multi-capability cloud-based communications solution provider that is engaged in the provision of cloud-based communication solutions.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 2012. It serves consumers across the globe, with a customer base that comprises of enterprises across various industries, including the energy, internet, industrial manufacturing, telecommunications, education and financial services industries.

The company’s objective is to improve the daily communication experience and operational activity for other businesses. It aspires to drive the transformation of the enterprise communications industry by providing SaaS-based tools, and operational and marketing tactics.

The enterprise provides a suite of cloud-based communications solutions including a communication platform as a service solution which offers application programing interfaces and software development kits to embed instant messaging, video and audio, voice call, messaging and other communications into a company’s business processes, services and/or applications. It also provides cloud-based contact centers, which offer 7moor and RongCC cloud solutions and allow enterprises to manage multi-channel consumer interactions with enhanced efficiency and lower costs. In addition to this, the enterprise also provides cloud-based collaborations and unified communications like RongVideo, which offer telephone, video and audio conferencing and instant messaging solutions.

The company is focused on expanding its cloud-based contact center to a more comprehensive tool that includes subsequent customer management mechanisms like social CRM. Equipped with a strong executive team and a highly efficient organization structure, this expansion will boost the company’s growth substantially and bring in more investors into the firm.

Cloopen Group Holding (RAAS), closed Monday's trading session at $4.77, off by 1.6495%, on 632,187 volume with 3,648 trades. The average volume for the last 3 months is 878,957 and the stock's 52-week low/high is $4.45860004/$59.00.

Infinity Pharmaceuticals (INFI)

MarketBeat, StreetInsider,, The Street, SmarTrend Newsletters, StockMarketWatch, Streetwise Reports, TraderPower, BUYINS.NET, Market Intelligence Center Alert, TradingMarkets, Zacks, MarketClub Analysis, Seeking Alpha, Hit and Run Candle Sticks, InvestmentHouse, DrStockPick, CRWEWallStreet, BestOtc, PennyStockProphet, Daily Trade Alert, Hototc, Investing Futures, Investment House, InvestorPlace, Jason Bond, CRWEPicks, Market FN, Buzz Stocks, Barchart, Greenbackers, QualityStocks, Weekly Wizards, Wealth Daily, Wall Street Mover, Trading Markets, Trades Of The Day, The Best Newsletters, StockOnion, StockHotTips, PennyOmega, SmallCap Network, Millennium-Traders, Promotion Stock Secrets, Profitable Trader Authority, PoliticsAndMyPortfolio, PennyToBuck, PennyStockScholar, PennyPro, AllPennyStocks, Penny Pick Finders, OTCtipReporter and SmallCapVoice reported earlier on Infinity Pharmaceuticals (INFI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (FRA: I3F) is a biopharmaceutical firm that is engaged in the discovery and development of new medications for cancer.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 1995, on March 22nd by Steven H. Holtzman. It serves consumers in the U.S. and operates as part of the pharmaceutical manufacturing industry, under the healthcare sector.

The company is party to collaboration agreements with Bristol Myers Squibb Company, F. Hoffman-La Roche Ltd and Arcus Biosciences Inc., and it has a strategic alliance with PellePharm Inc. which entails the development and commercialization of rights to its IPI-926 inhibitor program. It also has a strategic alliance with Verastem Inc., for the development, commercialization and manufacture of duvelisib and formulations which contain duvelisib; and another alliance with Intellikine Inc., entailing the discovery, development and commercialization of pharmaceutical products which target the gamma and/or delta isoforms of P13K.

The enterprise uses small molecule drug technologies to develop its products. Its product pipeline is made up of an orally administered clinical-stage immune-oncology product candidate known as IPI-549, which inhibits the phosphoinositide-3-kinase-gamma enzyme. The formulation is currently undergoing a phase 1/1b clinical trials evaluating its effectiveness in treating ovarian cancer, solid tumors and triple negative breast cancer.

The firm recently reported data from its IPI-549 trial, which shows that the formulation improves outcomes for patients with 2 distinct cancer types. The success of this formulation will not only greatly benefit patients suffering from triple negative breast cancer and metastatic urothelial cancer, but also bring in more investors into the firm, which will have a positive effect on the company’s growth.

Infinity Pharmaceuticals (INFI), closed Monday's trading session at $2.93, up 38.2075%, on 75,656,077 volume with 204,170 trades. The average volume for the last 3 months is 5.336M and the stock's 52-week low/high is $0.87559998/$5.98000001.

Moving iMage Technologies (MITQ)

BUYINS.NET reported earlier on Moving iMage Technologies (MITQ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Moving iMage Technologies Inc. (NYSE American: MITQ) is a digital cinema firm that is focused on designing, manufacturing, integrating, installing and distributing custom and standard designed equipment and other cinema products for cinema requirements.

The firm has its headquarters in Fountain Valley, California and was incorporated in September 2003 by Thomas Lipiec, Phil Rafnson, Glenn H. Sherman, David Richards, Jerry van de Rydt, Bevan Wright and Joe Delgado. It operates as part of the commercial and service industry machinery manufacturing industry in the United States. The firm serves consumers in Mexico, the U.S. and internationally.

The company’s services and products are focused on the needs related to the equipping, modernization and building of movie exhibition theatres.

The enterprise offers proprietary rack mount pedestals; assembled and in-house designed products to support alternative auditorium configurations and boothless theatre designs; automation systems for digital cinema applications; and assembled and in-house designed dimmers and lighting products. It also distributes cinema serves and projectors and provides demand controlled ventilation systems; premium sound systems and enclosures; and aisle lighting products, tablet arms, concession trays and tables, and cup holders for theaters. This is in addition to offering Cinergy, which enables an exhibitor to manage, monitor and store digital cinema log files in a centralized and secure location; and software solutions, including a cinema presence management and remote control system known as CineQC.

The firm was recently awarded a $1.6 million contract by Alamo Drafthouse Cinema to provide various cinema products to Alamo’s new Rhode Island location. This move not only brings in revenue to the firm but also helps extend its consumer reach to a new location, which will be good for the company’s growth.

Moving iMage Technologies (MITQ), closed Monday's trading session at $3.87, off by 0.257732%, on 290,482 volume with 1,595 trades. The average volume for the last 3 months is 3.113M and the stock's 52-week low/high is $3.78780007/$27.3076.

Shineco (TYHT)

StockMarketWatch, InvestorPlace, StreetInsider, MarketClub Analysis, QualityStocks, MarketBeat, TraderPower, BUYINS.NET, PoliticsAndMyPortfolio, HotOTC, OTCtipReporter, Penny Pick Finders, PennyStockScholar, Profitable Trader Authority, Promotion Stock Secrets, SeeThruEquity Research, StockOnion and PennyStockProphet reported earlier on Shineco (TYHT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Shineco Inc. (NASDAQ: TYHT) is focused on the production, distribution and sale of health and well-being focused plant-based products.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 1997, on August 20th. Prior to its name change in June 2005, the firm was known as Beijing Tenet Jove Technological Development Co. Ltd.

The company operates through the Herbal products, Luobuma products and Other agricultural product segments. The Herbal products segment is involved in processing and distributing traditional Chinese medicinal herbal products and other pharmaceutical products while the Luobuma segment is engaged in developing, manufacturing and distributing textile products, specialized fabrics and other by-products derived from Apocynum Venetum, which is an indigenous Chinese plant. On the other hand, the Other products segment is involved in planting, processing and distributing organic and green agricultural produce as well as cultivating Chinese Yew trees. The company sells its textile products under the Tenethealth brand as well as through 3rd party e-commerce websites, distributors and sales personnel. It sells its medicinal products in various pharmacies and on the Anhui Bozhou medicine transaction market.

The enterprise grows and sells yew trees which are used to produce anti-cancer medication and sells ornamental bonsai trees which purify indoor air quality. It also provides logistics services for agricultural products.

The company recently appointed a new CEO who has extensive experience in the capital market and the healthcare industry. The company’s chairman noted that this change would bring in new opportunities for Shineco Inc.’s future development, which would be good for the firm’s growth.

Shineco (TYHT), closed Monday's trading session at $3.8, off by 4.0404%, on 235,674 volume with 1,095 trades. The average volume for the last 3 months is 780,058 and the stock's 52-week low/high is $2.0999999/$19.3964996.

C-Bond Systems (CBNT)

TaglichBrothers, SmallCapVoice, OTPicks, MarketBeat, Penny Pick Insider, Cannabis Financial Network News, KingPennyStocks, PennyDoctor, MassiveStockProfits, Jet-Life Penny Stocks, Penny Stocks VIP, StockRunway, Daily Stock Motion, Wallstreet Profiler, QualityStocks, Fast Money Alerts, DSR News,, Penny Stock Hub, Zacks, SmallCapGrowth, Stock Shock and Awe, Stockgoodies, Wall Street Equities Research and Penny Stock General reported earlier on C-Bond Systems (CBNT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

C-Bond Systems Inc. (OTC: CBNT) is a nano-technology firm that is focused on owning, developing, manufacturing and selling patented C-Bond technology in the U.S.

The firm has its headquarters in Houston, Texas and was incorporated in 2007, on November 13th. Prior to its name change in 2013, the firm was known as WestMountain Alternative Energy Inc. The firm operates as a part of the business services sector industry and serves consumers in the U.S. Its primary focus is the window film and glass industry.

The enterprise operates in 2 divisions, i.e. C-Bond Safety Solutions and C-Bond Transportation Solutions. The former division is involved in the sale of disinfection products, C-Bond BRS; which are ballistic-resistance film systems, C-Bound Secure; which are window film mounting solutions and multipurpose strengthening primer. In addition to this, the enterprise is focused on implementing proprietary nanotechnology processes and applications which improve properties of sustainability, functionality and strength in porous material systems.

The company’s products include the C-Bond Ballistic Resistant Film system and C-Bond I, as well as the C-Bond NanoShield. The BRS comprises of carbon nanotube technology film mounting solution and security film product while the NanoShield is a multipurpose water repellant and glass strengthener solution that has been designed to reduce windshield damage caused by cracking and chipping.

The firm recently filed for a provisional patent with the Patent and Trademark Office to develop a nano-liquid chemical solution indicated for the repair of cracks and chips in windshield glass. Once brought to the market, the solution will become a popular and cost-effective way to handle windshield replacements and repairs, given that the cost of windshields grows higher each day.

C-Bond Systems (CBNT), closed Monday's trading session at $0.044, up 29.4118%, on 1,850,014 volume with 73 trades. The average volume for the last 3 months is 592,079 and the stock's 52-week low/high is $0.006899999/$0.25.

IMD Companies (ICBU)

PennyStocks24, Xtremepicks, OurHotStockPicks, Pumps and Dumps, OTC Stock Review, smartOTC, StockOrange, EmergingStockPlays,, Liquid Pennies, Fast Moving Stocks, QualityStocks, HEROSTOCKS,, AddictivePennyStocks, OTC Picks,,, VipStockReports, VIP STOCK ALERTS, Bull Trends, Penny Stock Rumble,, Stock Brain, ShazamStocks, ChartPoppers, Damn Good Penny Picks, Greenbackers, EpicVIP Group, Blaque Capital Stocks, AwesomeStockPick, Epic Stock Picks, Innovative Marketing, InsideBulls, Investors Chatroom, Center Stage Stocks, Promotion Stock Secrets, Value Penny Stocks, TheMicrocapNews, Stocktamer, StockPickVIP, StockPicks, Stockgoodies, Stock Tips Network, Penny Stock Newsletter, RagingStock Bull, MajorPennyStocks, PricelessPenny, PREPUMP STOCKS, Penny Trackers, Penny Stock Professor, Orbit Stocks, MicrocapVoice, MarketWireStocks and SmallCap Fortunes reported earlier on IMD Companies (ICBU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

IMD Companies Inc. (OTC: ICBU) is a holding firm which is engaged in the manufacture, marketing and distribution of equipment for the hydroponics industry. This is in addition to developing and manufacturing environmental controllers.

The firm is based in Tampa, Florida and was incorporated in 1993, on March 31st. It operates through its subsidiaries, which include PCI HeartScan, Optimum Mobile Imaging LLC, Lumz n Blooms Ltd Corp and R-Quest Hydroponics Inc. R-Quest Hydroponics Inc. is a software and hardware manufacturing firm.

The company’s primary products and services lie in the medical diagnostics services and health and fitness nutraceutical markets. The company, which plans to expand into the weight-loss industry, aims to combine the expertise of their team to develop a cohesive force which will boost the firm’s position in the marketplace.

The enterprise provides the new environmental master controller system, which offers management for grow room facilities for indoor gardens. The system, dubbed EMC-5000 also controls and regulates all features of an indoor grow system, including co2 level control, nutrient pumps, fans and light cycles, which promote growth. One of its subsidiaries has a base of consumers in both Canada and the United States. It also provides Optimum Mobile Imaging, which focuses on mobile imaging technology offered to patients.

The firm recently launched a cryptocurrency farming operation in Silicon Slopes. This move will allow the firm to set a standard for cryptocurrency farming as well as enable it to become a leading farming operation in the cryptocurrency market. This will boost its revenue as well as its popularity, which will be beneficial to both its stocks as well as its stakeholders.

IMD Companies (ICBU), closed Monday's trading session at $0.0083, up 31.746%, on 66,431,970 volume with 742 trades. The average volume for the last 3 months is 54.795M and the stock's 52-week low/high is $0.000199999/$0.046500001.

TGI Solar Power Group (TSPG)

OTCReporter, Mina Mar Marketing Group, Actual Gains,,,, OTC Picks, MadPennyStocks, BullRally, CoolPennyStocks, HotOTC,,,,,, StockEgg, PennyInvest, PennyStockVille, Pumps and Dumps, StockRich, WiseAlerts,, Honest Abe, Stock Traders Chat, TheMicrocapNews, TooNiceStocks, Epic Stock Picks, QualityStocks and Stocks Gone Wild reported earlier on TGI Solar Power Group (TSPG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TGI Solar Power Group Inc. (OTC: TSPG) is a holding firm that is focused on the provision of project management consulting services as well as the development of custom tools software and a line of electric vehicles.

The company has its headquarters in Ewing, New Jersey and was incorporated in 1967. It operates as part of the business services sector industry and serves clients across the globe. Prior to their name change in June 2008, the firm was known as TenthGate International Inc. As of July 31, 2017, the firm had not generated any revenue.

The firm is engaged in the development of patented technologies, processes and components and also designs a method with commercial value that will afford the firm a competitive market advantage and help generate shareholder value. It intends to offer clients resources, tools and management services to deliver real-time, interactive on demand staffing for project based and full time personnel.

Its services include software and app development, international business, IT, analysis and strategies, project management, business consulting, assessment and planning, and research and development services.

As of March 2020, the firm had made a move to expand its operations in Europe by acquiring an equity stake in Auxilium Energy. This venture is a strategic alliance for both firms and will allow TGI to add to their portfolio and also facilitate their expansion into other countries, including Germany, Ukraine and Italy. Additionally, the firm recently launched its SMART CITY Pilot Project in Mexico, which will implement TGI technologies.

TGI Solar Power Group (TSPG), closed Monday's trading session at $0.0094, up 29.4766%, on 25,127,960 volume with 349 trades. The average volume for the last 3 months is 2.774M and the stock's 52-week low/high is $0.001/$0.085.

Western Magnesium Corporation (MLYF)

We reported earlier on Western Magnesium Corporation (MLYF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Western Magnesium Corporation’s goal is to be a low-cost producer of green, primary magnesium metal. This is a strategic commodity valued for its strength and light weight. The Company earlier relocated and redomiciled in the United States. Western Magnesium’s focus is to play a significant role in supplying increasing U.S. demand for magnesium metal and alloys.

The Company formerly went by the name Nevada Clean Magnesium, Inc. It changed its name to Western Magnesium Corporation in May of 2019. Incorporated in 1966, the Company lists on the OTC Markets’ OTCQB.

Western Magnesium looks to use a continuous silicothermic process to produce magnesium. This process substantially lessens labor and energy costs relative to current methods and processes. It does so while being environmentally friendly.

Magnesium is a highly reactive metal and it is vital for photosynthesis. It is the lightest of all structural metals. Moreover, it is the third most common structural metal. Additionally, magnesium burns bright and is used in fireworks and flares. Magnesium also aids in the creation of stable, strong, lightweight alloys.

In April of 2020, Western Magnesium announced that it started the build out of its first commercialized pilot plant. Led by its technical team of Mr. Robert Odle, Chief Process Engineer, and Mr. Paul Sauvé, VP, Operations, Western Magnesium contracted an international engineering firm to assist in the design and procurement of the pilot plant.

Western Magnesium stated that this is a stepping-stone to move the Company forward in producing the first run of metal. This metal will be used to carry out end-user industry testing as well as obtain industry certification by the automobile, aerospace, and airline industries, and also the government and military.

The company recently announced (in conjunction with developments at the commercialized pilot plant) the development, buildout, and completion of its magnesium reactor. This furnace will be the first of its kind, and a major step towards being able to operate a silicothermic reactor system from open atmosphere to a sealed vacuum space on a continuous basis. This is very disruptive technology with controllable parameters from an efficiency, energy, and environmental standpoint. A continuous internally heated reduction furnace of this nature coupled with the proprietary Western Magnesium condenser will allow for maximum continuous production from pit or stockpile, to magnesium metal, to the end-user in timely manner. A process that assembly line manufacturers have longed for.

Western Magnesium Corporation (MLYF), closed Monday's trading session at $0.29, up 20.4319%, on 1,305,927 volume with 211 trades. The average volume for the last 3 months is 315,531 and the stock's 52-week low/high is $0.076899997/$0.328799992.

Innovation Pharmaceuticals, Inc. (IPIX)

QualityStocks, TopPennyStockMovers and Stockdigest Report reported earlier on Innovation Pharmaceuticals, Inc. (IPIX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Innovation Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is developing a world-class portfolio of innovative therapies addressing many areas of unmet medical need. These include inflammatory diseases, cancer, infectious disease, and dermatologic diseases. The Company previously went by the name Cellceutix Corporation. It changed its name to Innovation Pharmaceuticals, Inc. in June of 2017. Founded in 2007, Innovation Pharmaceuticals has its corporate office in Wakefield, Massachusetts. The Company lists on the OTC Markets’ OTCQB.

Innovation Pharmaceuticals’ Brilacidin is a versatile compound with extensive therapeutic potential. It is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints. This includes lessening the incidence of SOM.

The Company’s plan is to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources. In addition, positive results were observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS). A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA (Food and Drug Administration)-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infection.

Innovation’s Kevetrin is a novel anti-cancer drug. Kevetrin is shown to modulate p53, often referred to as the “Guardian Angel Gene” because of its crucial role in controlling cell mutations. Kevetrin has successfully completed a Phase 2 trial in Ovarian Cancer.

Innovation Pharmaceuticals previously announced that the FDA approved Innovation’s Investigational New Drug (IND) application to proceed with clinical trials of Brilacidin in COVID-19.

Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19 (see NCT04784897). Innovation Pharma is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation. Brilacidin has shown potent and consistent inhibition in vitro against coronaviruses, alphaviruses and bunyaviruses (with laboratory testing against other viruses also underway), supporting Brilacidin’s potential to be developed as a broad-spectrum antiviral. The annual global antiviral drug market is estimated to reach $44 billion by 2026.

Innovation Pharmaceuticals, Inc. (IPIX), closed Monday's trading session at $0.33, up 22.177%, on 2,052,810 volume with 393 trades. The average volume for the last 3 months is 1.068M and the stock's 52-week low/high is $0.155000001/$0.50.

Exicure, Inc. (XCUR)

PCG Advisory, QualityStocks, MarketBeat, StockMarketWatch and InvestorsUnderground reported earlier on Exicure, Inc. (XCUR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Exicure, Inc. is the pioneer in gene regulatory and immunotherapeutic drugs employing proprietary Spherical Nucleic Acid (SNA™) technology. A clinical-stage biotechnology company, it is developing therapeutics for neurology, immuno-oncology, inflammatory diseases, and also other genetic disorders based on its proprietary SNA technology. SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. Established in 2011, Exicure has its corporate headquarters in Chicago, Illinois. The Company’s shares trade on the Nasdaq Global Select Market.

Exicure’s belief is that its proprietary SNA architecture has distinct chemical and biological properties, which may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not normally addressed with other nucleic acid therapeutics. The Company is in preclinical development of XCUR-FXN, an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA).

The design of Exicure's proprietary SNA™ architecture is to unlock the potential of therapeutic oligonucleotides in a broad array of cells and tissues. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics. This is safe and effective delivery into cells and tissues. The Company’s Intellectual Property (IP) portfolio includes greater than 135 pending patent applications and more than 60 allowed or issued patents.

Exicure’s pipeline also includes Cavrotolimod (AST-008). Cavrotolimod (AST-008) is a toll-like receptor 9 agonist. The design of it is to activate the innate immune system and induce a potent anti-cancer immune response, particularly in combination with checkpoint inhibitors.

Exicure, Inc. (XCUR), closed Monday's trading session at $1.81, up 34.0741%, on 107,654,470 volume with 209,780 trades. The average volume for the last 3 months is 427,606 and the stock's 52-week low/high is $1.34000003/$2.82999992.

True Leaf Brands, Inc. (TRLFF)

QualityStocks and CFN Media Group reported earlier on True Leaf Brands, Inc. (TRLFF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

True Leaf Brands, Inc. is a wellness company for people and their pets. The Company lists on the OTC Markets and has two operating divisions. These are: True Leaf Cannabis, Inc.; and True Leaf Pet, Inc. True Leaf Brands has its corporate headquarters in Vernon, British Columbia.

The Company’s Founder, Darcy Bomford, has greater than 30 years of experience in the pet care industry. True Leaf Brands veterinary advisory team is chaired by Dr. Katherine Kramer, who is a champion of integrative care for pets.

The Company’s True Leaf Cannabis is a Licensed Producer (LP). True Leaf Cannabis owns True Leaf Campus, which is an 18,000 square foot facility situated on a 40-acre site zoned for the cultivation, processing, and sale of cannabis, and also general industrial use, in Lumby, British Columbia.

True Leaf Pet is a worldwide pet care company. True Leaf Pet offers plant-focused wellness products, which improve the quality of life for companion animals. True Leaf Pet says that it is guided by its corporate mission to "Return the Love" that was inspired by the unconditional love that pets give every day.

Ture Leaf Brands’ focus is natural support for pet companions. The Company’s family of products include Hemp Leaf CBD (cannabidiol) - Enhanced Calming and Hip + Joint Support; Hemp Seed - Calming, Hip + Joint, and Everyday Omega; and Oil of Oregano - Body + Oral Health Support. True Leaf Brands uses premium, naturally sourced ingredients.

The Company’s products include specially designed chews, oils, and also sticks. These are veterinarian-formulated. In addition, they contain human-grade, natural ingredients sourced from around the world. True Leaf’s unique formulations combine active ingredients with proven benefits that act together synergistically.

True Leaf Brands, Inc. (TRLFF), closed Monday's trading session at $0.2, up 27.9591%, on 48,005 volume with 27 trades. The average volume for the last 3 months is 49,722 and the stock's 52-week low/high is $0.135900005/$1.50.

The QualityStocks Company Corner

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC)

The QualityStocks Daily Newsletter would like to spotlight AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC).

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) was featured today in a publication detailing various investment considerations and how the company is “One to Watch.”

  • AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection
  • The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people approach cancer screening
  • CDA is powered by a database of over 200,000 samples and cases, providing a new way to approach disease and cancer screening
  • The company’s management team comprises professionals in both the United States and China who are knowledgeable and well educated in cancer screening and detection
  • The global cancer diagnostics market is expected to reach $249.6 billion by 2026

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance.

AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is situated in Philadelphia, Pennsylvania. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States.

Cancer Differentiation Analysis (CDA)

Cancer Differentiation Analysis (CDA) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form.

Most liquid-based cancer screening and detection technologies focus on biochemical signals, like conventional biomarkers and genomic signals, such as ct-DNAs and CTCs (circulating tumor cells in the blood). These typically only determine whether or not cancer has occurred at a fixed point in time.

CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future – all through a standard blood test, at a competitive price point.

AnPac Bio-Medical’s CDA is powered by a database of over 200,000 samples and cases and serves as a new way to approach disease and cancer screening. The device uses an integrated system of sensors to detect several biophysical signals at the cellular, protein and molecular levels. CDA leverages a proprietary algorithm to synthesize the data, effectively generating a personalized risk assessment for evaluated patients.

Through CDA technology, AnPac Bio-Medical aims to address a number of goals, including:

  • Innovate – AnPac Bio-Medical is an innovator in the cancer screening industry, with CDA research ongoing since 2008, and commercial operations beginning in 2015. AnPac considers itself a thought leader in developing multi-cancer screening.
  • Detect – AnPac Bio-Medical detects early signals of threatening cancer and its location within the body.
  • Identify – CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity rates.
  • Provide – The company’s platform provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms, which results in accurate and easy-to-understand results.
  • Proven – A fully operational analysis of over 200,000 test samples has been run to date. CDA technology has been shown to identify pre- and early-stage cancers in patients previously diagnosed as “cancer-free” through traditional methods.
  • Biophysical Properties – CDA analyzes biophysical properties in human blood and the correlation between biophysical properties and cancer occurrence.

Market Outlook

AnPac Bio-Medical is exploring detection of other types of cancers leveraging its innovative CDA technology and multi-cancer screening and detection tests, which could open significant opportunities on the global cancer diagnostics market.

According to a report by Grand View Research, the cancer diagnostics market is expected to reach $249.6 billion worldwide by 2026 ( The market is expected to grow at a CAGR of 7% during the forecast period.

Management Team

Dr. Chris Yu is the Co-Founder and Chief Executive Officer of AnPac Bio-Medical. He has enjoyed a successful career as an innovator in life sciences, technology and engineering. Dr. Yu has worked for three U.S. Fortune 500 companies and is the first/principal inventor of over 300 patent applications spanning semiconductors, materials and life science. He has a proven history of developing cutting-edge products with long-term profit and sustainability. Dr. Yu was born to a medical doctor’s family and went to medical school. He later switched his major to physics and received his bachelor’s and master’s degrees in physics from the University of Missouri-Kansas City Campus and a doctoral degree in physics from Pennsylvania State University. Both of his dissertations addressed innovative detection techniques.

Dr. Herbert Yu is the Co-Founder and Chief Medical Officer of AnPac Bio-Medical. He is a renowned expert in molecular epidemiology, with training in medicine and chemical biochemistry. Dr. Yu has a 20-year career in leading-edge cancer research, including breakthrough work in areas of carcinogenic factors. He is a professor and research director at the University of Hawaii and an adjunct professor at Yale University. He received his bachelor’s degree in medicine from Shanghai First Medical College. Dr. Yu also received a science degree in epidemiology and a Ph.D. in clinical biochemistry from the University of Toronto.

Jingiu (Edward) Tang is the company’s Chief Financial Officer. He previously served as a global internal auditor at Natuzzi S.p.A. Mr. Tang also worked at Beijing Dongshen CPA and Shanghai De’an CPA, providing external audits, finance and tax advisory services across different industries and sectors. He is a Certified Public Accountant in Australia. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University, and his bachelor’s degree in law from Southwest University of Science and Technology in China.

Weidong Dai is the company’s China General Manager. He previously served as a general partner at Stirrfir Investment Management Co. Mr. Dai has also served as the chairman of RTS Management (Shanghai) Co., and as managing director of Hong Kong Pro-Health Technology Co. and Shanghai Pro-Health Medical Devices Co. He has published a number of medical research papers and research articles in professional journals. Mr. Dai was awarded the Hong Kong Industrial Award for a medical device that he led in research and development. He earned his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from the Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.

AnPac Bio-Medical Science Co. Ltd. (ANPC), closed Monday's trading session at $3.95, up 1.8041%, on 59,361 volume with 295 trades. The average volume for the last 3 months is 1.051M and the stock's 52-week low/high is $3.15000009/$12.0900001.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX).

  • Lexaria just completed dosing for its second human clinical study, HYPER-H21-2 
  • The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBD
  • The company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United States
  • Lexaria also expanded its intellectual property portfolio with the allowance of its second patent in Japan
  • It also received US$3,817,643 from warrant exercises, proceeds from which will be used to advance the company’s research and development program and for its general corporate purposes

Lexaria Bioscience (NASDAQ: LEXX) has been making incredible strides in 2021 as it works towards achieving its business plan objectives. At the beginning of the year, the company set out to conduct three human clinical studies, two of which are underway at the time of this article.  Its most recent human clinical study, HYPER-H21-2, dosing was completed in July 2021 and was designed to understand better the human response to Lexaria’s DehydraTECH 2.0-enabled CBD ( The company projects that preliminary results would be available for reporting either in September or earlier.

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 19 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Monday's trading session at $6.41, up 2.8892%, on 414,378 volume with 1,248 trades. The average volume for the last 3 months is 1.945M and the stock's 52-week low/high is $3.97510004/$12.50.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CLXPF)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (OTC: CLXPF).

A recent study published in the “Consciousness and Cognition” journal has found that language produced while an individual is under the influence of LSD shows decreased semantic coherence and increased entropy levels. In layman’s terms, this means that people were more likely to move from one topic to another and have more disorganized speech while under the influence of LSD. The diverse (both good and potentially adverse) effects of psychedelic compounds such as LSD may explain why sector players including Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) prefer to concentrate their R&D efforts on developing medicinal formulations to be administered under the watchful eye of trained medical professionals.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin ( Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF), closed Monday's trading session at $3.18, up 4.2623%, on 1,098,177 volume with 1,658 trades. The average volume for the last 3 months is 625,828 and the stock's 52-week low/high is $0.493800014/$3.38000011.

Recent News

Ideanomics Inc. (NASDAQ: IDEX)

The QualityStocks Daily Newsletter would like to spotlight Ideanomics Inc. (NASDAQ: IDEX).

  • Ideanomics (NASDAQ: IDEX), a company focused on the convergence of financial services and industries experiencing technological disruption, today announced that it has made a strategic investment in Prettl Electronics Automotive (“PEA”). According to the update, PEA is a business unit within the Prettl Group, a large German industrial company that manufactures and distributes components and systems for the automotive, energy and electronics industries. The deal terms include a strategic investment of €7.5M (~$9M) for a 30% ownership stake, under which Ideanomics will receive exclusive sales and distribution rights for PEA charging infrastructure products and solutions in North America. In addition, IDEX CEO Alf Poor will join PEA's board of directors. To view the full press releases, visit and
  • Electrification will play a crucial role in the future as the world tries to move away from fossil fuels and cut down on carbon emissions. Presently, electric vehicles comprise a small percentage of the vehicles on America’s roads. Most electric vehicle (“EV”) models are too expensive for the average driver, and the country’s network of public charging stations still leaves a lot to be desired. With EV prices steadily reducing, investing in electric vehicle charging infrastructure is the next best way to boost EV adoption. The push for electrification has mostly been limited to light-duty passenger vehicles, but when medium- and heavy-duty electric buses and trucks are included in the analysis, the number of job years increase. In California, the number would be bumped by an extra 9,090 job years, and all these stations would require constant maintenance, providing even more jobs. With the country struggling to recover from the ongoing COVID-19 recession, electrification could provide thousands of much-needed jobs. Such research highlights how diverse the contribution of companies in the electric vehicle value chain, such as Ideanomics Inc. (NASDAQ: IDEX), is in terms of creating downstream jobs as well as protecting the environment from further degradation.

Ideanomics Inc. (NASDAQ: IDEX) is a global company facilitating the adoption of commercial electric vehicles and supporting next-generation financial services and fintech products. Ideanomics is currently divided into two divisions – mobility and capital. These divisions provide shareholders with access to disruptive and high-growth opportunities.

The company expects 2021 to be another growth year after it raised approximately $400 million over the past six months. This funding has already been put to good use with acquisitions of Wireless Advanced Vehicle Electrification (WAVE) and Timios. With roughly $200 million still on the balance sheet, Ideanomics continues to look for new investments and acquisitions in revenue-based opportunities focused on EV and fintech businesses.

Founded in 2004, Ideanomics is headquartered in New York, New York, with additional offices in Hangzhou, Beijing and Qingdao, China. Its current operations span the United States, China, Ukraine and Malaysia.

Ideanomics Mobility

Ideanomics Mobility is focused on the EV market. The global commercial EV market was valued at $34.7 billion in 2018 and is expected to grow at a CAGR of 39.9% through 2022 to reach a total of $132.73 billion ( According to a survey by Grand View Research, the global EV charging infrastructure market is also expected to grow and reach $144.97 billion in 2028, expanding at a CAGR of 33.4% from 2021 to 2028.

This growth is expected to be driven by increased support of electric vehicles from the public, as well as the current U.S. administration, which has a goal of achieving a 100% clean-energy economy.

The Ideanomics Mobility unit consists of five companies:

  • Mobile Energy Global (MEG) – Wholly owned China-based service provider of the Sales-to-Finance-to-Charging (S2F2C) business model to assist commercial fleet operators on EV enablement. Recent sales include 2,000 units of D1, BYD’s custom electric ride-hailing vehicle.
  • Medici Motor Works – Wholly owned North America division. MMW will develop zero-emissions specialty vehicles, trucks, buses and vans for the North American market.
  • Wireless Advanced Vehicle Electrification (WAVE) – Wholly owned Utah-based commercial EV charging technology company with a specialized offering of in-ground wireless charging for commercial vehicles. WAVE’s chargers power the Antelope Valley Transportation Authority, the largest municipal EV bus system in the country. Its revenue for 2020 exceeded $7 million, and it boasts a robust pipeline for 2021 and beyond.
  • Treeletrik – Majority investment in Malaysian-based OEM will service a high-demand market – electric delivery mopeds. Treeletrik has obtained certifications in Thailand and Indonesia, with orders secured for 2021. Its North American marketing program is expected to commence in 2021. As a part of the ESG initiative, one tree will be planted for every unit sold.
  • Solectrac – Minority investment in California-based electric tractor company. Solectrac manufactures 100% electric tractors to benefit farmers, crops and the planet at a time when the agriculture market remains virtually unaddressed by EV solutions.
  • Silk EV – Minority investment in hyper car and performance car design company, which provides access to the high-end battery and charging technology development ecosystem.

Ideanomics is generating EV revenue from its Sales to Financing to Charging (S2F2C) business model, which features three operating areas:

  1. Vehicle and Battery Sales: Medici, Treeletrik and Solectrac cover three key market segments
  2. Financing, Leasing and Insurance: Offering financial services to fleet customers, commission delivery and origination fee-based revenue
  3. Charging and Energy Services: Offering charging as a service, battery swap programs and WAVE wireless charging products

Ideanomics Capital

Ideanomics Capital is focused on providing disruptive fintech solutions across the entire board of financial services, ranging from financial markets to digital securities and assets to mortgages and more. More mainstream institutions and a growing number of companies have increased their digital securities services, along with institutional investments boosting bitcoin and the emergence of favorable regulatory developments, creating ample opportunities for widespread adoption of financial technologies.

Additionally, the U.S. real estate industry is ripe for technologization, as it currently is fragmented, antiquated, opaque and largely untouched by tech innovation. However, the expanding market, with U.S. home sales expected to grow 21.9% in 2021, and the increased digitization of all business spaces are expected to promote a digital-first experience as the new industry standard this year and beyond (

The Ideanomics Capital unit consists of five companies:

  • Timios – Wholly owned subsidiary bringing real estate into the 21st century by providing value-add, fee-based services addressing the title and closing process of home buying and mortgage transactions. Timios works to create transparency and efficiency within the market. Timios ended 2020 as a cash flow and EBITDA positive business.
  • The Delaware Board of Trade (DBOT) – Wholly owned FINRA-regulated ATS and broker dealer based in Delaware.
  • Liquefy – Minority investment bringing innovation to investment in real assets with blockchain technology by increasing efficiency in fractional ownership, lowering entry to investment barriers and unlocking liquidity in assets that were previously illiquid.
  • Technology Metals Market (TM2) – Minority investment in UK company delivering a direct investment and trading market for technology metals with a newly accessible technology metals asset class for inventory diversification. The traded metals are 100% backed by physical metals.
  • Intelligenta – Investment providing AI and machine learning solutions for financial institutions and regulators.

Management Team

Alf Poor is Ideanomics’ Chief Executive Officer. He is a client-focused and profit-driven executive who has a track record of success in rapidly growing technology companies and large, multi-national organizations. Mr. Poor’s expertise includes business planning, financing and creating and implementing corporate governance policies, as well as handling management across organizations. His specialization is working with cross-border and multi-national startups. Before taking the CEO role at Ideanomics, he was the CEO for Global Data Sentinel.

Conor McCarthy is the company’s Chief Financial Officer. He is a strategic and operationally oriented management-level professional. His extensive international experience is within the fintech, data science and advertising technology sectors. Mr. McCarthy has experience with public companies, PE, and VC-backed firms. His specializations are financial and management reporting, planning and analysis, financial modelling, performance metrics, KPIs, venture borrowing, Series A equity funding, ERP system implementation, international business operations, and acquisition due diligence and integration. Before joining Ideanomics, Mr. McCarthy most recently held a CFO position at OS33. Prior to that, he was CFO for Intent Media Inc.

Kate Lam is the company’s Managing Director of Financial Products. She is highly regarded for her fixed income capital marketing skills across Asia and the United States. Ms. Lam has over 25 years of experience in the financial markets industry, dealing with many asset classes and clients. Having spent a few years in the fintech startup industry, her skills bridge the gap between traditional financial assets and new technological innovations. She has held senior management positions at Bear Sterns, Deutsche Bank and Standard Chartered Bank.

Keith Byers is Ideanomics’ Senior Vice President of Operations. He has extensive experience managing strategic relationships with key clients and deepening the relationships through innovation and successful engagement strategies. Before Ideanomics, Mr. Byers was the Managing Partner and Head of Operations for Gain Theory. He has a Master of Arts – MA, Economics from Heriot-Watt University and a Master of Science – Economics from The University of Edinburgh.

Tony Sklar is the company’s Senior Vice President of Investor Relations. He is a communication strategist and has worked for multi-faceted companies with global operations. Mr. Sklar handles omni-channel distribution using intelligence platforms and data insights for strategic planning, international expansion and marketing channels. His specialties include project management with digital strategy and transformation, ICO, marketing, blockchain and strategic partnerships. In addition to his role with Ideanomics, he is also a board member for the Delaware Board of Trade and the host and senior technology reporter for Far From TV.

Ideanomics Inc. (IDEX), closed Monday's trading session at $2.39, up 0.843882%, on 7,153,819 volume with 21,340 trades. The average volume for the last 3 months is 17.277M and the stock's 52-week low/high is $0.800000011/$5.5300002.

Recent News

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

Shares of The Alkaline Water Company Inc. (NASDAQ:WTER) traded today at $2.17, eclipsing its 52-week high. This new high was reached on below average trading volume as 608,000 shares traded hands, while the average 30-day volume is approximately 2.3 million shares. Alkaline Water Co Inc is engaged in the business of distributing and marketing bottled alkaline water for retail consumers in different sizes. The firm sells its product in 500ml, 700ml, 1-liter, 1.5-liter 3-liter, and 1-gallon sizes. Its only operating geographical segment being the United States of America. The company sells its product to convenience stores, natural food products stores, large ethnic markets, and national retailers.

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform ( and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Monday's trading session at $2.19, up 11.7347%, on 10,029,332 volume with 23,870 trades. The average volume for the last 3 months is 1.818M and the stock's 52-week low/high is $0.930000007/$2.28999996.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

A mandate from the Centers for Medicare and Medicaid Services directed that from Jan. 1, 2021, all hospitals in the United States provide pricing information online about their services and items. The objective of this mandate is to help inform patients about the cost of procedures and services before they receive them. The disparities in the costs incurred by thyroid cancer patients make a strong case for personalizing treatment modalities in the way that is exemplified by what companies such as Predictive Oncology (NASDAQ: POAI) are doing since a customized protocol stands a higher chance of improving patient outcomes, thereby lowering costs incurred in the long term.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.


Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Monday's trading session at $1.14, up 0.884956%, on 649,226 volume with 1,389 trades. The average volume for the last 3 months is 2.826M and the stock's 52-week low/high is $0.629999995/$2.29999995.

Recent News

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

Despite its youth and immaturity, America’s state-legal cannabis industry has been dubbed one of the fastest-growing sectors in the country. The sector has generated billions of dollars in revenue for businesses and provided jobs for hundreds of thousands of people. In addition, projections have the space pulling in $43 billion by 2025. Cannabis is a high-risk industry and potentially a high-reward industry, especially for companies that can weather the risks, and many businesses are looking to throw their hats into the ring. It goes without saying that cannabis companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) that have a presence in Michigan have contributed to making the industry successful.

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.


Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.


Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.


Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 ( Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Monday's trading session at $0.8617, up 3.3399%, on 108,432 volume with 103 trades. The average volume for the last 3 months is 343,725 and the stock's 52-week low/high is $0.330000013/$1.64999997.

Recent News

Petroteq Energy Inc. (TSXV: PQE) (PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (TSXV: PQE) (PQEFF).

 Petroteq Energy (TSX.V: PQE) (OTC: PQEFF) (FSE: PQCF), an oil ‎company focused on the development and implementation of its proprietary oil-‎extraction ‎technologies, has announced results of a third-party review of its operating data, process simulation data and Front End Engineering and Design ("FEED") study. The review was conducted by Kahuna Ventures LLC, an engineering firm that provides engineering, design and full-project execution services to midstream oil and gas limited partnerships. The technical review indicates production costs of an estimated $22 per barrel of oil produced, and the FEED study includes a production train capable of processing 5,000 barrels of oil per day (“bopd”) from mined oil sands ore. According to the announcement, the company anticipates that this FEED could be the starting basis for future 5,000 bopd train designs for use in Utah by Petroteq and potentially by additional licensees in Utah as well as other locations in the United States and even around the world. To view the full press release, visit

Petroteq Energy Inc. (TSXV: PQE) (PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil sands exploration and production on mineral leases in Vernal, Utah, and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 2,500-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Clean Oil Recovery Technology (CORT) System.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ. PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy Chairman Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

“API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy Inc. (PQEFF), closed Monday's trading session at $0.137, up 1.5567%, on 1,654,704 volume with 163 trades. The average volume for the last 3 months is 3.986M and the stock's 52-week low/high is $0.032999999/$0.249500006.

Recent News

American Cannabis Partners

The QualityStocks Daily Newsletter would like to spotlight American Cannabis Partners.

  • ACP’s strategy is based on leveraging opportunities in real estate and licensing in states that have recently passed legalization legislation
  • Focused on complementary business segments — real estate, acquisition and development of proprietary assets, and ongoing cultivation operations, ACP appears poised for expansion
  • Company seeks partnerships with companies with aligned personal, ethical, and business sensibilities to differentiate itself in assets, services, research, and philanthropy

American Cannabis Partners (“ACP”) is a licensed, large-scale, and 100% organic cultivation company supplying multiple forms of raw product at consistent wholesale prices for manufacturing, distribution, and retail licenses. The company is considering additional growth via numerous initiatives, including expansion opportunities through partnerships and joint ventures in New Jersey, New York, Virginia, Nevada, Arizona, Missouri, and Massachusetts (

American Cannabis Partners (ACP) is a multi-state cannabis company with 560,000 square feet of licensed canopy space for cultivation and one retail license. The company is nationally headquartered in Trinity County of Northern California’s Emerald Triangle.

ACP is focused on three complementary business segments: real estate, acquisition & development of proprietary assets, and ongoing cultivation operations. Led by a seasoned management team with 30+ years of canna-business experience, ACP’s strategy is to capture opportunities in real estate and licensing in states that have recently passed cannabis legalization legislation, thereby equipping the company to capitalize on Federal interstate commerce opportunities.

Through its current cultivation operations, ACP supplies approximately 80% of its whole flower products for manufacturing, distribution and retail licenses. With the remaining 20%, the company supplies its proprietary strains to select California distributors and its own Michigan retail location under its exclusive in-house brand, ZÜK.

History of American Cannabis Partners

In 2014, Stephen Jordan, President of ACP, took on the Director of Operations position for a U.S.-based company operating in the Jamaican cannabis space. Over the course of his three-year tenure in this role, Jordan developed a number of relationships that would help serve as the basis of American Cannabis Partners.

One such relationship was with Junior Gordon, a cultivation lead grower from Jamaica’s Westmoreland Parish. Jordan immediately saw the value of Gordon’s unique skillset and credentials, and Gordon recognized Jordan’s heartfelt vision of bringing Jamaican culture to the rapidly developing U.S. cannabis space.

Guided by that mission, ACP’s unchanging goal is to improve the lives of individuals through cannabis and business.

Current Operations

Since its founding in 2018, privately-owned American Cannabis Partners has established a foothold in two key U.S. cannabis markets – California and Michigan. In total, the company has acquired 12 cannabis licenses, including 20,000 sq. ft. of cultivation licenses in California and 540,000 sq. ft. of cultivation licenses & one retail license in Michigan.

ACP’s IP portfolio features three proprietary strains sold exclusively through the company’s wholly owned ZÜK brand, as well as proprietary data collection and mining systems supporting its cultivation and retail operations.

Plans for Expansion

American Cannabis Partners is pursuing additional growth in the cannabis sector through multiple planned initiatives. These include:

  • Submitting applications for additional cultivation licenses at the company’s Trinity County, California, location;
  • Planning land acquisition and project development strategies for expanding operations to its third U.S. state beginning in the second quarter of 2022; and
  • Planning land acquisition and project development strategies for expanding operations to its fourth U.S. state beginning in the second quarter of 2024.

ACP is currently exploring expansion opportunities through partnerships and joint ventures in New Jersey, New York, Virginia, Nevada, Arizona, Missouri and Massachusetts.

Management Team

Stephen Jordan is the CEO of American Cannabis Partners. He is focused on the first and last steps of legal cannabis – cultivation and retail. To date, Mr. Jordan has provided the company with ownership of 12 licenses, three proprietary cannabis strains and multiple real estate assets. His background in cannabis operations and financial strategies has guided American Cannabis Partners’ efforts to produce consistently high-quality product for both the medical and recreational segments. Mr. Jordan has operated under cultivation, manufacturing, distribution, medical research (Univ. of West Indies), retail and exportation licenses in multiple countries, further strengthening his network within the cannabis industry.

Gary Coltek is the company’s Chief Operating Officer. He has credentials based in the culinary, hospitality and sustainability industries spanning over 40 years, including taking three companies public. Mr. Coltek has held management positions internationally with Ritz Carlton, Four Seasons, Trump Hospitality, Phymatrix and International Oncology Network. For 17 years, he was the founding member and partner of a private boutique consulting firm. He is currently a guest speaker and visiting professor at universities in Israel, China, Italy, the Netherlands and Peru, covering topics that include culinary sustainability, sustainable cannabis farming, organic sustainable farming and cannabis clinical studies.

Scot C. Crow is the Lead Corporate Counsel for American Cannabis Partners. He has extensive experience in corporate mergers & acquisitions and tax law. His clients rely on him to advise them with respect to their complex financial transactions and provide outside general counsel. Mr. Crow provides his clients proactive advice with respect to sensitive management matters, litigation management, day to day transactional needs and objective assessments for the development of successful business strategies. His experience includes serving as lead counsel for numerous mergers & acquisitions, private equity investments, private offerings, venture capital financings, mezzanine debt offerings, divestures and other related transactions, with an emphasis in the legalized marijuana segment.

Jacob Frenkel is the company’s Lead Compliance Counsel. He is the current Chair of Dickinson Wright’s Government Investigations and Securities Enforcement Practice. Mr. Frenkel’s solutions-minded approach to issues has earned him a reputation as an aggressive, tenacious, creative and proactive defense lawyer and litigator. After 14 years as a Senior Counsel in the SEC’s Division of Enforcement, U.S. federal criminal prosecutor and New Orleans Assistant District Attorney, Mr. Frenkel has practiced in the private sector for 20 years. His unique mix of corporate transactional, litigation and investigations defense clients extend well beyond the cannabis industry and cover a wide range of industries worldwide.

Junior Gordon is the Director of Cultivation for American Cannabis Partners. With 30 years of international cannabis cultivation experience in both the Caribbean and United States, Mr. Gordon is recognized as one of the top growers in the world. His skills span both controlled indoor and large volume outdoor harvest programs, giving him proficiency in nursery, propagation and indoor & outdoor grow strategies. As a winner of High Times and other notable Cannabis Cups, his focus is on connecting the dots between propagation, soil, irrigation, planting, harvesting, curing, processing and inventory control, bringing Jamaican cannabis cultivation best practices to American Cannabis Partners’ operations.

Recent News


Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, has reported second-quarter financial results for the period ended June 30, 2021. Noteable numbers include the announcement that UUUU has $98.8 million — $79.4 million in cash and marketable securities and $29.2 million in inventory — working capital and that the company saw a net loss of $10.8 million, which included a non-cash, mark-to-market increase in warrant liabilities of $3.6 million resulting from a significant increase in the company's share price. The report also noted that Energy Fuels is ready to provide uranium for the proposed U.S. Uranium Reserve once it is established by the U.S. government as well as for markets around the world. The company reported that it has begun ramping up to commercial-scale production of a mixed rare earth element (“REE”), actually delivering RE carbonate to a European separation facility last month. To view the full webcast, visit To view the full press release, visit

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Monday's trading session at $5.15, off by 1.9048%, on 1,829,296 volume with 7,858 trades. The average volume for the last 3 months is 3.289M and the stock's 52-week low/high is $1.41999995/$7.82999992.

Recent News

Perpetual Industries Inc. (OTC: PRPI)

The QualityStocks Daily Newsletter would like to spotlight Perpetual Industries Inc. (PRPI).

  • Bloomberg article reports that sales of classic cars have remained “positively stable” during global pandemic
  • Two key acquisitions help firmly establish PRPI’s position in multibillion-dollar classic car market
  • CEO notes that PRPI’s acquisition of Worldwide Auctioneers will lead to company’s greater growth

While COVID-19 may have dampened the new-car market, a recent Bloomberg article noted that the global pandemic had little impact on the sales of classic cars ( That’s good news for Perpetual Industries (OTC: PRPI), which earlier this year announced two key acquisitions — the Worldwide Group LLC, operating as Worldwide Auctioneers, and AutoGrafic Software System — both aimed at firmly establishing the company’s position in a multibillion-dollar classic car market.

Perpetual Industries Inc. (OTC: PRPI) is an incubator for the development of innovative, energy-efficient technologies aimed at commercializing products that have the potential to impact and advance a wide range of industries on a global scale.

The company’s team of experts and trusted industry partners have the resources to provide essential components needed to take projects from their initial stages through to the end products. Perpetual Industries values strict controls and high levels of quality through all stages of research, development, manufacturing and commercialization.

Perpetual Industries was founded by President, Chairman and CEO Brent W. Bedford in 2005. It is located in Auburn, Indiana.

R&D Portfolio Overview

Perpetual Industries is expanding expertise and knowledge of energy-efficient technology by developing low-cost, green energy solutions for various industries, including artificial intelligence, blockchain mining, graphic rendering, renewable energy, cloud computing and internet of things (IoT), all while continuing research, development and commercialization of its proprietary XYO Balancing Technology in key applications.

XYO Balancing Technology

XYO Balancing Technology delivers high-performance solutions for inefficiencies that commonly affect rotating equipment, machinery and devices. It is designed to harness rotor displacement energy to move compensating masses and automatically correct for imbalances, effectively reducing vibration.

Key highlights of the company’s XYO Balancing Technology include:

  • Customized XYO balancers can be created for almost everything that rotates, providing virtually unlimited potential applications.
  • XYO Balancing Technology is optimized specifically to eliminate vibration in rotating equipment and enable environmentally responsible products to operate more efficiently.
  • Leveraging a proprietary design, XYO Balancing Technology is the result of over 25 years of research and development effort.

WindSilo – Vertical Axis Wind Turbine

Implementing its proprietary XYO Balancing Technology, Perpetual Industries’ WindSilo turbine improves balancing issues that are common in most wind turbines today. The company’s design is engineered to allow for much faster spin speeds and greater energy output.

The company believes that this innovative turbine design could eliminate the expensive traditional methods of balancing wind turbines while increasing their performance, reliability and efficiency.

In November 2020, Perpetual Industries announced that Trine University, a private post-secondary institution located in Angola, Indiana, had been awarded a grant to assist the company in the development of the WindSilo.

The XYO Washing Machine

Perpetual Industries is currently developing a proprietary domestic washing machine design implementing XYO Mechanical Balancers to dynamically compensate for variable mass imbalance during the spin cycle. The company expects these efforts to produce a number of benefits, including higher spin speeds, reduced energy consumption, decreased noise emissions and less mechanical wear & tear.

The company’s research shows tremendous market potential for a more efficient washing machine design. With an estimated 70 million washing machines produced annually and over 500 million used daily, even a small reduction in energy consumption could be pivotal. Reducing energy usage of all washing machines by just 15% would save enough energy to power the city of Milan. Perpetual Industries’ energy efficient design is expected to reduce energy usage by up to 50%.

Prototype testing of Perpetual Industries’ design has established the XYO Washing Machine as highly effective at reducing vibration when built into the spin basket assembly.

Green Energy Mining System

Using its expertise and knowledge of environmentally friendly technologies, Perpetual Industries is developing low cost, environmentally responsible energy solutions for powering large scale blockchain mining operations.

The company’s Green Energy Mining (GEM) System is being hailed as the next generation of energy efficient cryptocurrency mining. Powered by renewable & surplus energy sources such as wind, solar, natural gas, wind and geothermal that utilize battery storage technology, the platform addresses rising demand for computing power.

Renewable Energy Market Outlook

The global renewable energy market was valued at $928 billion in 2017 and is expected to continue expanding at a CAGR of 6.1%, resulting in a value of $1.5 trillion by 2025, according to Allied Market Research ( Hydroelectric power is projected to be the most lucrative segment of the entire global renewable energy industry, followed by the wind, bioenergy, solar and geothermal segments.

Worldwide Auctioneers Acquisition

In January 2021, Perpetual Industries announced its acquisition of The Worldwide Group LLC, operating as Worldwide Auctioneers.

Worldwide Auctioneers is a U.S.-based boutique auction firm specializing in the sale and acquisition of classic vintage motorcars at auction around the globe. With an impressive 20-year history and a talented team, Worldwide offers an extensive range of personalized services to collectors, including private sales, appraisal, collection direction and consultancy, estate planning and asset management.

Perpetual Industries expects Worldwide to benefit from multiple channels of collaboration moving forward, particularly within the company’s blockchain division.

Classic Car Market Outlook

The U.S. classic car market has recorded steady expansion over recent years, accounting for revenue of approximately $12.63 billion in 2020, according to Statista ( The same report forecasts growth to $15.52 billion by 2023, representing a CAGR in excess of 7 percent. Classic car dealers in the U.S. have cornered a significant portion of this market opportunity. According to data from IBISWorld (, the market for classic car dealers in the U.S. was valued at $2.1 billion in 2021, achieving a CAGR of 1.5% from 2016 to 2021, despite the challenges associated with the COVID-19 pandemic.

Management Team

Brent W. Bedford is the President, Chairman, CEO and founder of Perpetual Industries. He has held these roles continuously since founding the company in January 2005. He has a deep understanding of every aspect of the company’s business, products and markets. He also has experience developing corporate strategies, assessing emerging industry trends and carrying out business operations. Mr. Bedford has a strong background in mechanical applications, with expertise in finance, private startups, public startups and corporate turnarounds.

Carl Dilley is Director and COO of the company. He is a career entrepreneur who has served as a C-level officer in many different companies across multiple industries. Mr. Dilley has been instrumental in taking over 400 companies public. He has been involved in the investment industry since 1983. He has held FINRA series 24, 66 and 7 Securities licenses, allowing him to perform retail, investment, banking and new listing services functions.

William Griffin Thomas, CPA, is the company’s CFO. He holds a Bachelor of Science in Accounting from the University of Tampa and a Bachelor of Science in Agribusiness from the University of Florida. Mr. Thomas is a licensed CPA with over 19 years of experience spanning both the private and public sectors, as well as time with non-profits. His expertise includes auditing, budget analysis, fixed assets, financial modeling, SEC financial reporting, GAAP compliance and fair value measurements.

Perpetual Industries Inc. (PRPI), closed Monday's trading session at $0.177, even for the day. The average volume for the last 3 months is 23,479 and the stock's 52-week low/high is $0.063000001/$0.925000011.

Recent News

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

The QualityStocks Daily Newsletter would like to spotlight Avricore Health Inc. (OTCQB: AVCRF).

  • Avricore Health signed the first amendment to its supplier distribution agreement between subsidiary HealthTab and Abbott
  • The amendment adds to the agreement Abbott’s ID Now(TM) molecular testing device, which will bring in onsite testing and reporting capabilities for SARS-CoV-2 (Covid-19), RSV, Influenza A & B, and Strep
  • Avricore also announced its partnership with Ellerca Health, which will see the companies use their respective technologies (Avricore’s HealthTab and Ellerca’s 360Care app) to support patient needs at community pharmacy level

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) recently made several key strides in its quest to become the world’s leader point-of-care technologies within community pharmacy. On July 26, the company announced the signing of the first amendment to its supplier distribution agreement between its wholly owned subsidiary and flagship offering, HealthTab(TM) Inc, and Abbott (NYSE: ABT), the global healthcare company and diagnostics leader, in Canada (

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab™ (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.


HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets and third-party app integration through API.

Agreement with Shoppers Drug Mart

In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2™ analyzers provided by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near Term Goals

Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies.

Market Outlook

In 2020, the global point-of-care testing (POCT) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (CAGR) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia.

Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia.

Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health Inc. (OTCQB: AVCRF), closed Monday's trading session at $0.1279, off by 8.1178%, on 2,547 volume with 5 trades. The average volume for the last 3 months is 8,472 and the stock's 52-week low/high is $0.013269999/$0.485619992.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading